A March 2026 Nature Reviews paper by Yücel and Gladyshev reframes aging as four linked failures of epigenetic fidelity — and makes the case that each is, in principle, reversible.
On March 27, 2026, a review paper appeared in *Nature Reviews* that sent ripples through the longevity research community. Authored by A. Doğa Yücel and Vadim Gladyshev — a leading aging researcher at Harvard Medical School and one of the world's foremost experts on longevity — the paper describes aging as the progressive failure of epigenetic fidelity: a systems-level collapse of the machinery that tells your cells who they are and what to do.
Within hours, David Sinclair — whose own 2023 *Cell* paper made a parallel case — called it "the best article in years."
This is a significant statement. Here's what the paper argues, why it matters, and what it means for the interventions available today.
The review identifies four interconnected processes that degrade over time, each feeding back into the others to accelerate biological aging:
The nucleus of your cell is not just a bag of DNA — it's a highly organized three-dimensional structure. DNA is organized into loops and domains called TADs (Topologically Associating Domains), which determine which genes are close to which regulatory sequences. The nuclear envelope, nuclear lamina, and chromatin contacts maintain this architecture.
As we age, this spatial organization deteriorates. Proteins that maintain nuclear structure decline. Chromatin contacts become disorganized. Genes that should be isolated from each other start interacting. The consequence is dysregulated gene expression — cells begin "cross-talking" in ways that shouldn't happen, contributing to inflammation, senescence, and loss of tissue identity.
This explains why aged cells show such dramatically altered transcriptomes even without mutations in the underlying DNA sequence. The book is the same, but the chapters have been shuffled.
The second failure is the disruption of epigenetic memory — the histone modifications and DNA methylation patterns that define cell identity. As described in the Sinclair lab's work, DNA repair events cause chromatin remodeling factors to temporarily misplace themselves, and over thousands of repair events, small errors accumulate into significant noise.
The authors frame this as a loss of epigenetic fidelity: the faithful transmission of epigenetic patterns from mother cell to daughter cell becomes less accurate over time. Differentiated cells gradually acquire features of less specialized cells. The more specialized a cell type, the more epigenetic information it must maintain — which may explain why neurons and cardiomyocytes (which rarely divide) are among the most vulnerable to epigenetic aging.
Histones — the proteins that DNA wraps around — are themselves subject to age-related changes. The paper highlights shifts in histone variants, particularly the replacement of canonical histones with variant forms like H3.3 as cells age. These variant histones alter how DNA is packaged and which genes are accessible.
Nucleosome remodeling is normally a tightly regulated process. With aging, the regulation degrades. Nucleosomes become less stable, and the orderly packaging of the genome becomes less precise. This is particularly notable in regions of the genome that should be permanently silenced — repetitive elements and transposable DNA that have been "locked away" by epigenetic marks. When these regions destabilize, transposons can activate, contributing to genomic instability and inflammation.
The fourth failure is the downstream consequence of the first three: altered transcription. Transcription factors — the proteins that bind to DNA and initiate gene expression — find themselves operating in a landscape that has changed. Enhancers (regulatory elements that boost gene expression) shift their activity. Gene networks become rewired.
The result is that aged cells have transcriptomes that look like a combination of their proper cell type and something less differentiated. This loss of transcriptional precision is called exdifferentiation — a partial reversal of the differentiation process that occurred during development. Exdifferentiation contributes to dysfunction across every tissue type.
A critical insight of the Yücel-Gladyshev review is that these four processes don't occur in isolation — they form feedback loops that amplify each other.
Deteriorated nuclear architecture disrupts TAD boundaries, allowing enhancers to activate off-target genes. This activates inflammatory pathways that generate oxidative stress, which causes more DNA damage, which causes more repair events, which causes more epigenetic disruption. Disrupted epigenetic marks change which transcription factors are active, which changes nucleosome positioning, which further degrades nuclear architecture.
Each failure makes the others worse. This is why aging tends to accelerate in later life — the system is not declining linearly but through compounding feedback.
This is the central question. The review engages with it directly, and the answer — carefully qualified — is yes, in principle, at least partially.
The evidence comes from several directions:
Partial reprogramming experiments (most prominently, Sinclair's OSK work) show that aged cells can have their epigenetic clocks reversed while maintaining their cell identity. The epigenetic information needed for youth appears to be stored, not destroyed. Cells can access it when given the right signals.
Senolytics (drugs and supplements that clear senescent cells) reduce one of the primary drivers of the SASP — the inflammatory signaling from zombie cells that accelerates epigenetic disruption in neighboring cells. Clearing senescent cells appears to partially reset the epigenetic environment in surrounding tissue.
NAD+ restoration supports sirtuin activity, which is central to both epigenetic maintenance (during DNA repair) and to metabolic regulation that affects chromatin state.
The paper is careful to note that human proof and causality remain to be established. The mechanism is compelling; the clinical translation is still ahead. But the logical framework for why epigenetic aging might be reversible in humans is now formally articulated in the highest-tier journal in biology.
Vadim Gladyshev is not a speculative thinker. His lab has produced foundational work on oxidative stress, thioredoxin systems, and selenium biology in aging. His epigenetic clocks and age-related biomarker work are among the most cited in the field.
When someone with Gladyshev's record of rigorous, skeptical science publishes a review arguing that aging is a systems failure of epigenetic information — and when Sinclair, who made the parallel argument years earlier, calls it the best paper in years — the scientific community takes notice.
This doesn't mean aging reversal is imminent. It means the scientific consensus is shifting: aging is increasingly viewed as a stochastic, information-based process that may have reversible components, not an inevitable wear-and-tear process that can only be slowed.
The review isn't primarily a clinical paper, but the mechanisms it describes map directly onto interventions that exist today.
The sirtuin-NAD+ axis is the most directly actionable target. Sirtuins (particularly SIRT1 and SIRT6) are responsible for maintaining histone modifications during DNA repair and for deacetylating histones in ways that stabilize the epigenome. NAD+ is their required cofactor.
Supporting NAD+ levels is therefore supporting epigenetic fidelity at the molecular level. The two primary approaches:
Histone variants and nucleosome stability are affected by several factors you can influence:
Spermidine (1–5 mg daily) is one of the few supplements with evidence for directly affecting histone function. It promotes autophagy of damaged cellular components and has been shown in population studies to associate with lower all-cause mortality. Sinclair's lab has also noted spermidine's effects on NAD+ metabolism.
Folate and methylated B vitamins support DNA methylation — the primary currency of epigenetic marks. Without adequate methyl groups (supplied by folate and B12 through the one-carbon metabolism cycle), methylation patterns cannot be maintained faithfully. Low folate is associated with global hypomethylation — a hallmark of epigenetically aged cells.
Nuclear architecture deteriorates partly because of the chronic inflammation driven by senescent cells. Clearing these cells reduces the SASP signals that disrupt the epigenetic environment:
Reducing oxidative stress — which drives DNA damage which drives epigenetic disruption — is also relevant. The most evidence-based approach is exercise, particularly Zone 2 cardio (Strong evidence), which simultaneously reduces oxidative load, boosts NAD+, and supports mitochondrial function.
The feedback mechanisms described in this paper mean that epigenetic aging can accelerate or decelerate based on your lifestyle choices. You can now measure this directly. Consumer-grade DNA methylation age tests have become available that use versions of the same clocks validated in academic research. Regular testing (every 6-12 months) provides feedback on whether your interventions are moving your biological age in the right direction.
The Yücel-Gladyshev review and the Sinclair Cell paper together form a coherent scientific narrative: aging is a systems failure driven by lost information, the information exists in a recoverable form, and the failure can be tracked and partially addressed.
This framing has profound implications for how we think about longevity interventions. It shifts the goal from "slowing damage accumulation" to "preserving and restoring informational fidelity." These are different targets with different intervention strategies.
In practical terms, it also provides a scientific rationale for treating biological age as a modifiable variable rather than a fixed trajectory. Your epigenetic age is not your fate. The tools to meaningfully influence it — NAD+ precursors, senolytics, lifestyle practices — are available now.
The therapies that will directly reprogram aging cells are coming. Understanding the mechanism they'll target helps you protect the system in the meantime.
For a full review of the evidence on epigenetic-targeting supplements, explore the NMN/NR intervention page (Limited evidence) and see how Vadim Gladyshev and David Sinclair frame these interventions within their broader research.
*As an Amazon Associate, Stacking Years earns from qualifying purchases. Product links above are provided for convenience and do not constitute medical advice.*